The Treatment and Progress in Consolidation Therapy of APL
10.13241/j.cnki.pmb.2017.22.047
- VernacularTitle:急性早幼粒细胞白血病巩固治疗现状及进展
- Author:
Yingying YU
;
Xiaoxia LI
;
Shuye WANG
;
Chengmin WANG
;
Wenyi HOU
- Keywords:
Acute promyelocytic leukemia;
Consolidation therapy;
Arsenite
- From:
Progress in Modern Biomedicine
2017;17(22):4394-4396,4400
- CountryChina
- Language:Chinese
-
Abstract:
Acute promyelocytic leukemia (APL) was considered to be the most rapidly fatal leukemia,because of serve clinical manifestation,high rate of early death and the low cure rate.APL has achieved great success due to the application of ATRA and ATO.Although the complete remission rate is about 90％,the relapse rate has been reported to be as high as 15％-30％.So reducing the recurrence and improving long-time survival have become the focus of the study.Choosing the reasonable treatment after remission is very important.The post remission therapy usually include consolidation therapy and maintenance therapy,but the optimal strategy has been controversy.Therefore,this artical will review the literature of APL in consolidation therapy.
